List of Excipients in Branded Drug ACETAZOLAMIDE

Generic Drugs Containing ACETAZOLAMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	acetazolamide	0143-9006	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	acetazolamide	0143-9006	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	acetazolamide	0143-9503	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in ACETAZOLAMIDE?

# Of NDCs	Excipient
1	ALCOHOL
3	AMMONIA
4	AMMONIO METHACRYLATE COPOLYMER TYPE A

Acetazolamide Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Acetazolamide is an established carbonic anhydrase inhibitor with limited value in new-molecule exclusivity and stronger potential in formulation, manufacturing, patient-access, and supply-chain improvements. The most credible opportunities are differentiated oral dosage forms, pediatric and dysphagia-friendly products, low-excipient formulations, preservative-free sterile presentations, and contract-manufacturing platforms. Generic competition is mature, so commercial success depends on price, supply reliability, regulatory simplicity, and a clinically meaningful dosage-form advantage.

What is the FDA regulatory status of acetazolamide?

Acetazolamide is an FDA-approved prescription drug used for glaucoma, edema, epilepsy, altitude sickness, and related conditions. It is marketed in oral tablets, extended-release capsules, and injectable presentations. The drug is available from multiple generic manufacturers and has long-standing clinical use.

Attribute	Acetazolamide status
Active ingredient	Acetazolamide
Pharmacologic class	Carbonic anhydrase inhibitor
Common strengths	125 mg and 250 mg immediate-release tablets; 500 mg extended-release capsules
Injectable presentation	Acetazolamide sodium for injection
FDA pathway	Abbreviated New Drug Application for most generic products
Prescription status	Prescription only
Reference product	Diamox and Diamox Sequels historically established the principal branded references
Main dosage-form risks	Tablet swallowing burden, bitter or difficult-to-mask taste, capsule size, injectable reconstitution, excipient intolerance
Biosimilar pathway	Not applicable; acetazolamide is a small molecule
Generic pathway	ANDA, subject to reference-product bioequivalence and applicable FDA requirements

Acetazolamide is not a biologic and does not create biosimilar exposure. Commercial competition is therefore driven by generic substitution, authorized or branded generics, reformulation, and supply execution rather than biosimilar interchangeability.

FDA labeling and inactive-ingredient information are product-specific. Sponsors must evaluate the exact label and approved composition for each reference product and strength before designing an ANDA or 505(b)(2) product. Public product records are available through DailyMed and FDA drug databases.[1,2]

What excipients are used in acetazolamide formulations?

Acetazolamide formulations commonly require excipients that address powder flow, compactability, disintegration, moisture sensitivity, taste, and release control. The appropriate strategy depends on whether the product is an immediate-release tablet, extended-release capsule, or sterile injectable.

Immediate-release tablets

Immediate-release acetazolamide tablets generally require a conventional solid-dose excipient system. Candidate functions include:

Formulation function	Candidate excipient classes	Commercial rationale
Dilution and compression	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Supports tablet weight, hardness, and manufacturability
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Sodium starch glycolate, crospovidone, croscarmellose sodium	Controls breakup and dissolution
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or permitted colorants	Improves handling, identification, and swallowability
Taste management	Film coat, ion-exchange resin, polymer barrier, flavor system	Relevant to pediatric or orally disintegrating products

A standard immediate-release tablet is usually the lowest-risk commercial route. It also has the weakest differentiation because many suppliers can reproduce a conventional formulation at low cost.

Acetazolamide has limited aqueous solubility characteristics that can make dissolution and content uniformity important development variables. Particle-size distribution, polymorphic form, milling conditions, granulation method, and lubricant concentration can affect dissolution and process performance. A sponsor should treat the active pharmaceutical ingredient and excipient combination as an integrated control strategy rather than selecting excipients only from compendial precedent.

Extended-release capsules

Extended-release acetazolamide products create a stronger formulation opportunity than conventional tablets. The objective is to reduce dosing frequency while preserving exposure and avoiding excessive early release.

Potential release-control systems include:

• Polymer-coated multiparticulates
• Ethylcellulose or ammonio methacrylate copolymer coatings
• Hypromellose matrix systems
• Hydrophilic or lipid-based matrix pellets
• Capsule-in-capsule systems
• Drug-layered beads with functional polymer coatings

A multiparticulate design may reduce the effect of localized dose dumping and can provide more consistent gastrointestinal distribution than a single matrix tablet. The tradeoff is greater manufacturing complexity, more dissolution-method development, and more demanding control of coating weight gain.

For a generic extended-release product, the formulation must match the reference product’s performance under a broad range of dissolution conditions. Alcohol-induced dose dumping, fed-versus-fasted behavior, gastric pH effects, and capsule opening behavior can become regulatory review issues.

Injectable acetazolamide sodium

The injectable product is a distinct excipient and manufacturing opportunity. Key development requirements include:

• Sterility assurance
• Endotoxin control
• Reconstitution time
• Solution clarity
• pH control
• Container-closure compatibility
• Stability after reconstitution
• Low particulate burden
• Appropriate osmolality and administration characteristics

Acetazolamide sodium for injection may be supplied as a sterile powder requiring reconstitution. Potential commercial improvements include ready-to-use liquid presentations, single-dose vials with more convenient reconstitution, prefilled syringes where clinically and economically justified, and pharmacy-ready packaging.

A ready-to-use product could reduce preparation steps, but it would introduce a higher stability burden. The sponsor would need to manage hydrolysis, pH drift, container interaction, and microbial risk. Lyophilization can improve stability but increases cycle development and cost.

What excipient strategy is best for acetazolamide?

The preferred strategy is a product-specific platform rather than one universal excipient formula.

Lowest-risk strategy: conventional immediate-release tablet

A conventional tablet using established excipients offers:

• Shortest development timeline
• Lower manufacturing cost
• Straightforward scale-up
• Familiar regulatory precedent
• Broad generic substitution potential

Its commercial weakness is low differentiation. Price competition can rapidly compress margins, especially where multiple ANDA holders have established supply.

Moderate-risk strategy: improved film-coated tablet

A film-coated tablet can target patients who experience swallowing difficulty, unpleasant mouthfeel, or tablet friability. The coating should be thin enough to preserve rapid dissolution and robust enough to reduce handling damage.

Commercial claims must remain within the approved labeling and applicable regulatory framework. A sponsor cannot assume that improved swallowability alone will support premium pricing unless it is linked to a defined patient or institutional purchasing need.

Higher-value strategy: pediatric-friendly formulation

Pediatric use creates a credible opportunity because conventional tablets may be difficult to administer accurately. Product concepts include:

• Oral solution
• Oral suspension
• Powder for reconstitution
• Dispersible tablet
• Orally disintegrating tablet
• Unit-dose sachet or stick pack

The main technical challenge is taste. Acetazolamide’s sensory profile can make simple sweetening inadequate. A successful system may require polymeric taste masking, complexation, coated particles, or a pH-controlled flavor approach.

Candidate excipients include suspending agents, wetting agents, sweeteners, flavors, buffers, preservatives where justified, and viscosity modifiers. The formulation must maintain dose uniformity throughout the in-use period and remain compatible with dosing syringes.

A preservative-free powder-for-reconstitution product may have a stronger commercial profile than a multidose liquid because it can reduce microbial-control complexity and improve shelf life. It also creates an additional reconstitution and labeling burden.

High-complexity strategy: modified-release multiparticulates

An extended-release multiparticulate product can create more defensible formulation know-how and potentially support a 505(b)(2) strategy if the product has a meaningful clinical or dosing advantage. The development burden includes:

• In vitro release matching
• Food-effect studies
• Dose-dumping assessment
• Multiparticulate uniformity
• Coating-process validation
• Packaging moisture control
• Potential clinical bridging

This route is suitable for a sponsor with formulation and oral-modified-release manufacturing capabilities. It is less attractive for a company seeking a rapid, low-investment generic launch.

What patents protect acetazolamide formulations?

The core acetazolamide molecule is an old active pharmaceutical ingredient, and the principal commercial market is generic. The central molecule therefore offers little practical new-product exclusivity. The more relevant intellectual-property categories are formulation, release profile, taste masking, device configuration, manufacturing process, and packaging.

IP category	Relevance to acetazolamide	Likely commercial value
Core compound patent	Historical and generally expired for a product of this age	Low
Immediate-release composition	May protect a specific excipient ratio or process, but design-around risk is high	Low to moderate
Extended-release composition	Can protect polymer system, multiparticulates, dissolution profile, or dosage regimen	Moderate to high
Pediatric taste masking	Can protect coated particles, resin complexes, or sensory-masking combinations	Moderate
Injectable presentation	May protect ready-to-use stability, container closure, or reconstitution system	Moderate
Manufacturing process	May protect granulation, coating, particle engineering, or sterile processing	Moderate
Method of use	Usually limited value where indications and clinical practice are established	Low to moderate
Packaging and device	Can protect unit-dose delivery or administration convenience	Moderate

The FDA Orange Book remains the primary source for patents and regulatory exclusivity associated with listed drug products.[3] A conventional generic acetazolamide tablet is unlikely to obtain meaningful market protection from the active ingredient itself. A differentiated formulation may rely on patents that cover the product rather than the molecule.

What method-of-use patents affect acetazolamide?

Acetazolamide has established indications, including glaucoma, edema, epilepsy, and prevention or treatment of altitude-related illness. Method-of-use patent value is constrained by the age of the drug and the breadth of existing clinical practice.

A new method-of-use strategy would require a clearly defined patient population, dosing schedule, combination regimen, or treatment setting. It would also face substantial validity and obviousness scrutiny because acetazolamide has an extensive literature base. For most sponsors, formulation and delivery claims are more practical than broad therapeutic-use claims.

When does acetazolamide lose exclusivity?

Acetazolamide’s original small-molecule exclusivity period expired long ago. The commercial market is therefore already open to generic competition. Current exclusivity, if any, would arise from a specific product, formulation, pediatric study, orphan designation, or newly approved indication rather than from the active ingredient.

A simplified exclusivity timeline is:

Period	Commercial status
Original development period	Innovator protection associated with the original compound and product
Historical post-approval period	Brand-led market with limited competition
Generic entry period	ANDA-based competition and multiple manufacturers
Current market	Mature generic market with reformulation and supply-chain opportunities

The key commercial question is not when the molecule loses exclusivity. It is whether a new acetazolamide product can obtain product-specific protection, qualify for a differentiated regulatory pathway, or win institutional contracts through better supply and administration characteristics.

What paragraph IV challenges and litigation affect acetazolamide?

Paragraph IV litigation is most relevant when a sponsor files an ANDA that challenges an unexpired patent listed for a reference product. For a mature acetazolamide product, the expected litigation exposure is generally lower for conventional immediate-release products than for newer extended-release, pediatric, or device-linked formulations.

Potential litigation triggers include:

• A patent listed against an extended-release product
• A formulation patent covering polymer composition or release profile
• A method-of-use patent included in the Orange Book
• A patent covering a ready-to-use injectable presentation
• A dispute over delisting, certification, or patent scope

A Paragraph IV certification can create a 45-day period for the patent holder to file an infringement action and may trigger a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[4] A sponsor should conduct a claim chart against every relevant Orange Book-listed patent before filing.

Settlement agreements involving acetazolamide would require case-specific review of the court docket, patent listing, filing date, and entry terms. No broad settlement-based market barrier should be assumed for the mature immediate-release market.

What commercial opportunities exist for acetazolamide?

Hospital and institutional supply

Sterile acetazolamide is used in hospital settings where product availability and preparation time matter. Commercial opportunities include:

• Reliable supply of injectable acetazolamide sodium
• Simplified reconstitution
• Reduced vial waste
• Unit-dose packaging
• Pharmacy-ready labeling
• Regional manufacturing redundancy

Hospitals may favor supply certainty over formulation novelty. A sponsor with validated sterile capacity can compete through contracting, fill-finish reliability, and shortage mitigation.

Pediatric and specialty pharmacy products

An oral liquid or dispersible product could serve children and adults with swallowing limitations. Specialty pharmacies, outpatient clinics, and caregivers may value:

• Accurate oral dosing
• Reduced crushing or manipulation
• Stable in-use performance
• Child-resistant packaging
• Oral syringes
• Clear storage instructions

Taste masking is the main product risk. A product that achieves acceptable palatability without an expensive or unstable excipient system has a stronger margin profile.

Altitude medicine and travel health

Acetazolamide is widely associated with altitude-related illness prevention. A compact, unit-dose, travel-oriented package could target consumers through prescription channels and travel clinics. The opportunity is commercial rather than patent-driven and would depend on distribution, brand positioning, and regulatory-compliant labeling.

Global markets

Geographic opportunities are strongest where supply is fragmented, branded products are expensive, or pediatric liquid availability is limited. Relevant markets include:

• North America for institutional supply and differentiated generics
• Europe for established generic and hospital channels
• Latin America for reliable oral products and cost-sensitive supply
• Asia-Pacific for manufacturing, export, and local pediatric demand
• High-altitude regions for travel and emergency medicine distribution

Regulatory requirements, permitted excipients, pharmacopoeial standards, and local bioequivalence rules vary by jurisdiction. An excipient acceptable in the United States may require separate review in Europe or other markets.

How strong is the acetazolamide patent estate?

The patent estate is weak for the core molecule and stronger only where a sponsor creates a specific formulation or delivery system. Patent strength depends on claim breadth, prior art, ease of design-around, reproducibility, and the commercial value of the protected feature.

A conventional tablet composition usually has limited defensibility because competitors can substitute diluents, binders, disintegrants, and lubricants while maintaining equivalent performance. Multiparticulate release systems, difficult-to-reproduce taste-masking architectures, and sterile ready-to-use products can produce stronger barriers, but they also require more extensive development and validation.

The most defensible strategy is a layered portfolio covering:

1. Composition of matter for the formulation system
2. Manufacturing process and critical process parameters
3. Dissolution or release profile
4. Taste-masking architecture
5. Container-closure or delivery system
6. Defined patient population or dosing regimen where supportable

How does acetazolamide compare with competing carbonic anhydrase inhibitors?

Product	Main commercial distinction	Excipient opportunity
Acetazolamide	Broadest historical use and mature generic supply	Pediatric, modified release, sterile supply, low-cost reformulation
Methazolamide	Oral carbonic anhydrase inhibitor used primarily in glaucoma	Differentiation through tolerability, dosing, and access
Dorzolamide	Topical ophthalmic carbonic anhydrase inhibitor	Preservative-free multidose or unit-dose ophthalmic systems
Brinzolamide	Ophthalmic suspension with formulation complexity	Suspension stability, comfort, and device performance

Acetazolamide has the broadest route-of-administration opportunity among these products because it is used in oral and injectable forms. Its disadvantage is mature generic pricing and limited molecule-level exclusivity.

Key Takeaways

• Acetazolamide is a mature generic small molecule with little remaining value in core-compound exclusivity.
• Conventional immediate-release tablets are the lowest-risk but least differentiated opportunity.
• Pediatric liquids, dispersible tablets, and taste-masked multiparticulates offer stronger commercial differentiation.
• Extended-release multiparticulates can support a more defensible formulation and patent strategy but require significant development.
• Injectable acetazolamide sodium offers opportunities in ready-to-use presentation, reconstitution, packaging, and hospital supply reliability.
• The relevant IP focus is formulation, process, release profile, taste masking, packaging, and device claims.
• Paragraph IV risk is generally lower for mature immediate-release products and higher for newer protected formulations.
• Biosimilar risk does not apply because acetazolamide is a small molecule.
• The strongest commercial positions will combine regulatory simplicity, reliable API and manufacturing supply, patient-use advantages, and a targeted patent portfolio.

FAQs

Can acetazolamide be developed as an oral solution?

Yes. An oral solution or suspension could address pediatric and swallowing-related needs. The critical development issues are taste masking, dose uniformity, chemical stability, microbial control, and compatibility with oral syringes.

Which excipients are most important for acetazolamide extended release?

The key excipient classes are release-controlling polymers, coating polymers, binders, fillers, lubricants, and moisture-barrier packaging components. Polymer selection must be tied to dissolution performance and food-effect behavior.

Is a new acetazolamide formulation eligible for 505(b)(2) approval?

Potentially, depending on the formulation, route, reference product, clinical differences, and regulatory strategy. A 505(b)(2) pathway may be relevant for a new dosage form or delivery system that cannot be approved through a standard ANDA.

Can acetazolamide obtain orphan-drug exclusivity?

Only if it is developed for a qualifying rare disease or condition and satisfies FDA orphan-drug requirements. Existing use of acetazolamide in common indications does not create orphan exclusivity.

What is the most attractive acetazolamide commercial niche?

Pediatric-friendly oral dosing and hospital-ready injectable supply are the most credible niches. Both address practical administration problems that are less exposed to direct price competition than a standard generic tablet.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
2. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certification and litigation provisions. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/percentage-new-drug-application-submissions-patent-certification-and-litigation-provisions